Impact of Changing the Appearance of Oral Cancer Medications on Adherence and Patient Experience
Official title: Impact of Changing the Appearance of Oral Antineoplastics on Adherence and Continuity of Treatment, Patient-reported Health Outcomes, and Patient Experience of Care
Run by Universidad Miguel Hernandez de Elche · NCT07664683 · Data updated 2026-11-12
This study tests whether changing how an oral cancer medicine looks or is packaged affects how well patients stick to their treatment and how they feel about their care.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 334 (estimated) |
| Sponsor | Universidad Miguel Hernandez de Elche Academic / other |
| Drugs / interventions | imatinib, chemotherapy |
| Locations | 1 site (San Juan, Alicante) |
| Status | Recruiting |
| Started | December 8, 2025 |
| Main results expected | July 2026 |
| Study ends | June 29, 2027 |
| Registry record updated | June 24, 2026 |
| Trial ID | NCT07664683 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults receiving one of the specified oral anticancer medications who have or will experience a change in appearance or packaging during the study period.
✕Probably not a fit
Patients who do not experience any change in pill appearance or packaging, or who are not on the listed medications, may not see a benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study will examine how changes in the appearance of oral antineoplastic medications (including brands switching to generics or between generics) influence treatment adherence, continuity, and patient-reported outcomes. It uses a mixed-methods approach with quantitative assessments of prescription changes and a qualitative focus on patient experiences, plus before-and-after analyses of key variables. The research covers several oral cancer drugs and aims to identify gender differences in responses to appearance changes. It is conducted across three hospitals in the specified region with collaboration from national health institutes. The study will help determine if appearance and packaging shifts affect real-world medication use and patient perspectives.
Why it matters
Potential benefit: If successful, findings could guide policies and packaging practices to support adherence and patient experience with oral cancer therapies.
How similar studies have gone: Prior work suggests appearance and packaging changes can influence medication adherence in some conditions, but evidence in cancer oral therapies is limited and this study explores it in this context.
Who can join: the full rules
Show full inclusion / exclusion criteria
Objective 1: Inclusion criteria: ANEOs included in the pharmacotherapeutic guide of the three hospitals for two years of follow-up (June 2025-2027) will be included. Objectives 2-5: Inclusion criteria: * Patients on treatment for at least 6 months with one of the following ANEOs will be included: capecitabine (L01BC06) (not used as adjuvant in short cycles), imatinib (L01EA01), everolimus (L04AA18), abiraterone (L02BX03) and lenalidomide (L04AX04), at the time of a change in their usual treatment (from brand to generic or between two generics). * Patients on treatment with ANEOs who meet the established criteria and who change their treatment from brand to generic or from one generic to another generic during the study period may also be included. Exclusion criteria: * Individuals who collect medication for others and those who are institutionalised will be excluded. * Patients who have been admitted to hospital in the last 4 weeks are also excluded, due to the increased control of their medication. Objective 2( Qualitative analysis) \- Spanish Patient Forum
Where it's running
-
Universidad Miguel Hernández
San Juan, Alicante, Spain Recruiting
Study contacts
- Study coordinator: Elsa Dr. Elsa López
- Email: elsa.lopez@umh.es
- Phone: +34 965919414
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Keeping up with home exercises for musculoskeletal conditions
This project will see how well adults with musculoskeletal conditions stick to personalized home exercise programs and which clinical, psychological, or demographic factors relate to sticking with them.
-
Health-Enhancing Adapted Physical Activity Program
This study is testing a 16-week exercise program to see if it helps people with chronic diseases stick to physical activity and improve their health.
-
Gyrotonic exercise for elders with breast cancer and Behcet disease
We’re testing whether a gyrotonic exercise program helps older people who have both Behcet disease and breast cancer.
-
PECS II vs SPSIP nerve blocks for pain after mastectomy
This study tests whether two ultrasound-guided nerve blocks (PECS II and SPSIP) differ in how much opioid patients need after mastectomy.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
Compare a new endoscopy-assisted breast-conserving surgery with the usual approach
This study tests whether a new endoscopy-assisted breast-conserving technique can provide similar or better cosmetic outcomes and safety compared with conventional breast-conserving surgery in women with early breast cancer who want to preserve their breast.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.